| Date Filed | Type | Description |
| 08/11/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
8-K
| Quarterly results |
| 07/03/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 05/30/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 04/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 03/20/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.6% stake in Protagonist Therapeutics, Inc. |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/15/2023 |
8-K
| Quarterly results |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/09/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Protagonist Therapeutics, Inc. |
| 01/31/2023 |
SC 13G/A
| BlackRock Inc. reports a 7.4% stake in Protagonist Therapeutics, Inc |
| 01/11/2023 |
SC 13G/A
| JOHNSON & JOHNSON reports a 5% stake in Protagonist Therapeutics, Inc. |
| 01/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 7.7% stake in AMENDED FILING PROTAGONIST THERAPEUTICS INC |
| 01/06/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/03/2023 |
SC 13G
| CITADEL ADVISORS LLC reports a 5.5% stake in Protagonist Therapeutics, Inc. |
| 12/12/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/05/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 08/04/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/11/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/02/2022 |
8-K
| Quarterly results |
| 05/05/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/26/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/13/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|